JP Errico appointed Chief Financial Officer at Ondine Biomedical

Ondine Biomedical Inc., a leading Canadian life sciences firm, has recently announced the appointment of Joseph P. (“JP”) Errico as their new Chief Financial Officer. In his new role, JP Errico will oversee the development and management of Ondine’s financial operations, as well as handle their capital markets interactions. His responsibilities will also include engaging with major health systems and clients, and contributing to the company’s overall growth strategies in financial and operational aspects.

JP Errico is renowned for his entrepreneurial success in the medical sector, having established, sold, or publicly listed multiple medical device and pharmaceutical companies such as ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore. His innovative products have impressively generated over $20 billion in sales.

Carolyn Cross, CEO and founder of Ondine, expressed her enthusiasm about JP Errico’s joining, highlighting his valuable experience in finance, capital markets, and medical technology development. She emphasized the significance of his role in Ondine’s global expansion and the pursuit of FDA approval in partnership with HCA Healthcare.

JP Errico shared his excitement about the potential Ondine holds in addressing antimicrobial resistance, a major global health challenge. He is eager to contribute to the company and praised the team’s dedication to bringing essential technology to the global market.

JP Errico’s academic credentials are impressive, with an undergraduate degree in Aeronautical Engineering from MIT and graduate degrees in Law and Mechanical/Materials Engineering from Duke University. He is also a qualified patent attorney.